Canadian biotech company Tryp Therapeutics (CSE: TRYP) is set to list on the ASX through a backdoor merger with genetic medicines developer Exopharm (ASX: EX1) in a $14.3 million acquisition agreement. Following this agreement, Exopharm will change its name to Tryp and re-list on the ASX. On completion of the Transaction (Completion), Exopharm will be
Read MoreAs news of billionaire (and controversial) business magnate Elon Musk taking “microdoses of ketamine (a dissociative drug)” to manage depression started doing the rounds, a bunch of divisive arguments popped up—is that just an excuse to justify the use of drugs or is there some hidden potential there? Biotech company Emyria (ASX: EMD) makes a
Read MoreAlthough it doesn’t apply to me, many of you may remember the early mornings during adolescence when you were throwing yourself around in a club, parading a locked-jaw, and beaming pupils so wide it would be hard to deny that you weren’t on something. Well, chances are, you had consumed MDMA, or if you were
Read MoreRhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the Australian Therapeutic Goods Administration (TGA) for approval. The filing is a significant milestone for the Company who are hoping to launch their product to market later this year. Rhythm’s test offers a convenient and non-invasive
Read MoreA heart attack can feel like literally anything. A sore arm, jaw pain, nausea… The list goes on. Difficulty in recognising a heart attack due to atypical symptoms increases for women, elderly and diabetics. The wide scope of symptoms can often result in costly emergency room visits and tests just to discover simple indigestion is
Read MoreBringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.